MTVA Projected Dividend Yield
MetaVia Inc ( NASDAQ : MTVA )NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and T2DM. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, and peptide YY. 21 YEAR PERFORMANCE RESULTS |
MTVA Dividend History Detail MTVA Dividend News MTVA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |